Advertisement

Triazenes pp 133-144 | Cite as

Triazenes: Therapeutic Considerations and Perspectives

  • G. Cartei

Abstract

Since the first reports on the synthesis of triazenes at the end of last century, triazenes received a certain attention by chemists. The demonstration that phenyl- and imidazole-dimethyltriazenes caused antitumor effects in laboratory animals led to a wider examination of the biological and pharmacological properties of this class of compounds. As a result of these earlier studies, DTIC has entered the clinical practice as an antitumor agent active against malignant melanoma, soft tissue sarcomas, Hodgkin’s lymphoma, APUD cell tumors, and it has also been used less frequently on other solid tumors.

Keywords

Soft Tissue Sarcoma Metastatic Malignant Melanoma Bacillus Calmette Guerin Advanced Malignant Melanoma Budd Chiari Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1).
    J.A. Montgomery, Experimental studies at Southern Research Institute with DTIC (NSC45388), Cancer Treat. Rep. 60: 125 (1976).PubMedGoogle Scholar
  2. 2).
    D.H. Cowan, and D.E. Bergsagel, Intermittent treatment of metastatic malignant melanoma with high dose 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC45388), Cancer Chemoter. Rep. 55: 175 (1971).Google Scholar
  3. 3).
    K.I. Pritchard, I.C. Quirt, D.H. Cowan, D. Osoba and, G.J. Kutas, DTIC therapy in metastatic malignant melanoma: a simplified dose schedule, Cancer Treat. Rep. 64: 1123 (1980).PubMedGoogle Scholar
  4. 4).
    G.J. Hill, G.E. Metter, S.E. Moss, and F.M. Golomb, DTIC therapy for melanoma: correlation of toxicity with response and longevity in 742 patients, AACR Proc. 17: 244 (1976).Google Scholar
  5. 5).
    G.J. Hill, S.E. Moss, F.M. Golomb, and G.E. Metter, DTIC and combination therapy for melanoma, Cancer 47: 25 (1981).CrossRefGoogle Scholar
  6. 6).
    G.J. Hill, G.E. Metter, E.T. Krementz, W.S. Fletcher, F.M. Colomb, G. Ramirez, T.B. Grage, and S.E. Moss, DTIC and combination therapy for melanoma. II. Escalating schedule of DTIC with BCNU, CCNU and vincristine, Cancer Treat. Rep. 63: 19 (1979).Google Scholar
  7. 7).
    M.K. Samson, L.H. Baker, G. Cummings, R.W. Talley, B. McDonald, and D.B. Bhathena, Clinical trial of chlorozotocin, DTIC and dactinomycin in metastatic malignant melanoma, Cancer Treat. Rep. 66: 371 (1982).PubMedGoogle Scholar
  8. 8).
    A. Kessinger, J.F. Foley, and, H.M. Lemon, Therapy of malignant APUD cell tumors. Effectiveness of DTIC, Cancer 51: 790 (1989).CrossRefGoogle Scholar
  9. 9).
    W. Blum, J.S. Greenberger, G.P. Canellos, and E. Frei, Successful treatment of metastatic sarcomas with cyclophosphamide, adriamycin and DTIC (CAD), Cancer 46: 1722 (1980).PubMedCrossRefGoogle Scholar
  10. 10).
    L. Nathanson, J. Walter, and J. Horton, Characteristics of prognosis and response to an imidazole carboxamide in malignant melanoma, Clin. Pharmacol. Ther. 12: 955 (1979).Google Scholar
  11. 11).
    G.A. Van Hazel, J. Rubin, and, C.G. Moertel, Treatment of metastatic carcinoid tumor with dactinomycin or dacarbazine, Cancer Chemother. Rep. 67: 583 (1983).Google Scholar
  12. 12).
    E.C. Borden, D. Amato, H.T. Enterline, H. Lerner, and P.P. Carbone, Randomized comparison of adriamycin regi mens for treatment of metastatic soft tissue sarcomas, ASCO Proc. 2: 231 (1983).Google Scholar
  13. 13).
    J.A. Gottlieb, L.H. Baker, J.M. Quagliarla, J.K. Luce, J. P. Whitecar, J.C. Sinkovics, S.E. Rivkin, R. Brownlee, and E. Frei, Chemotherapy of sarcomas with a combination of adriamycin and DTIC, Cancer 30: 1632 (1972).PubMedCrossRefGoogle Scholar
  14. 14).
    M. Lopez, S. Carpano, L. Di Lauro, P. Vici, and E.M.S. Conti, Treatment of advanced soft tissue sarcomas with epirubicin and DTIC, 5 th Europ. Conf. Clin. Oncol. ECCO5, London 3–5 sept. 1989, Abst. P-0462.Google Scholar
  15. 15).
    M.J. Mastrangelo, A.R. Baker, and H.R. Katz, Cutaneous melanoma, in: “Cancer principles and practice of oncology,” V.T. De Vita, S. Hellmann and S.A. Rosenberg, eds., II Edition, Lippincott, Philadelphia, 1371 (1985).Google Scholar
  16. 16).
    R. Oratz, J.L. Speyer, M.D. Green, R. Blum, J. Wernz, D. Roses, M. Harris, and F.M. Muggia, DTIC and cisplatinum chemotherapy in metastatic malignant melanoma, ASCO Proc. 6: 208 (1987).Google Scholar
  17. 17).
    C. Portlock, J. Murren, A. Buzaid, C. Davis, and W. DeRosa, High dose cisplatin and dacarbazine in metastatic melanoma, ASCO Proc. 8: 284 (1989)Google Scholar
  18. 18).
    J. Casal, A.J. Movano, C. Crespo, A. Marques, L. Carbanas, and R. Moreno, Ifosfamide and DTIC in metastatic malignant melanoma. An effective combination, 5 th Europ. Conf. Clin. Oncol. ECCO5, London 3–7 sept. 1989, Abst. P-0602Google Scholar
  19. 19).
    W. Campbell, O. Beloqui, P. Herranz, M. Santos, M. Sureda, V. Hidalgo, A. Gil, E. Barrajon, and F.A. Calvo, Ifosfamide, doxorubicin, dacarbazine and amphotericin B in metastatic soft tissue sarcoma: preliminary results of a phase II study, AACR Proc. 29: 222 (1988).Google Scholar
  20. 20).
    C. Charnsangavej, V.P. Chuang, S. Wallace, C.S. Soo, and T. Bowers, Angiographic appearance of recurrent malignant melanoma before and after intra-arterial chemotherapy, Radiology 142: 347 (1982).PubMedGoogle Scholar
  21. 21).
    T.L. Loo, E.A. Strasswender, J.H. Jardine, and E. Frei III, Clinical pharmacological studies on 5-(dimethyltriazeno)-imidazole-4-carboxamide (NSC 45388), AACR Proc. 8: 42 (1967).Google Scholar
  22. 22).
    G. Cartei, T. Ceschia, P. Marsilio, L. Clocchiatti, G. Fasola, G. Morandini, D. Galletti, and A. Sibau, Effectiveness and toxicity of BELD polychemotherapy in advanced malignant melanoma, Tumori 75: 229 (1989).PubMedGoogle Scholar
  23. 23).
    G. Cartei, A. Bononi, G. Interlandi, F. Cartei, and A. Cantone, Alizapride nell’antiemesi durante monochemioterapia con cis-DD-platino, Atti Sec. Congr. Naz. Soc. Ital. Cure Palliative, 16 dicembre 1989, p. 96.Google Scholar
  24. 24).
    J.K. Luce, W.G. Thurman, B.L. Isaacs, and R.W. Talley, Clinical trial with the antitumor agent 5-(dimethyltriazeno)imidazole-4-carboxamide (NSC 45388), Cancer Chemother. Rep. 54:119 (1970).PubMedGoogle Scholar
  25. 25).
    F. Ley, M. Winzer, M. Weber, and M. Hypa, Budd-Chiari-Syndrom nach Dacarbacin (DTIC) therapie bei malignem Melanom — ein vermeidbarer Zwischenfall, Z. Hautkr. 60:961 (1985).Google Scholar
  26. 26).
    C. Erichsen and P-E. Jonsson, Venoocclusive disease after dacarbazine therapy (DTIC) for melanoma, J. Surg. Oncol. 27: 268 (1984).PubMedCrossRefGoogle Scholar
  27. 27).
    H. Swensson-Beck and W.H. Trettel, Budd Chiari syndrom bei DTIC-therapie, Hauzart 33: 30 (1982).Google Scholar
  28. 28).
    E.F. McClay, M.J. Mastrangelo, R.E. Bellet, and D. Berd, An effective chemo hotmonal therapy regimen for the treatment of disseminated malignant melanoma, ASCO Proc., 6:208 821 (1987).Google Scholar
  29. 29).
    J.H. Paulusma-DeWaal, F.T. Bosman, H.R.A. Fischer, P.C. Van der Velden, and W.H.L. Hackeng, The glucagonoma syndrome, Neth. J. Med. 25: 127 (1982).Google Scholar
  30. 30).
    F.K. Storm, L.R. Kaiser, J.E. Goodnight, W. Harrtson, R.S. Helliott, P.H.D. Antoniette, S. Gomes, and D.L. Morton, Thermochemotherapy for melanoma metastases in liver, Cancer 49: 1243 (1982).PubMedCrossRefGoogle Scholar
  31. 31).
    A. Franchi, S. D’Atri, E. Bonmassar, D. Piccioni, F. Mandelli, F. Malagnino, M. Masi, and G. Papa, High dose dacarbazine in acute leukemia: preliminary immunotoxicological studies, Farmaci e Terapia 5 (suppl. 5): 63, (1988)Google Scholar
  32. 32).
    G. Cocconi, M. Bella, F. Calabresi, M. Tonato, R. Canaletti, C. Boni, F. Buzzi, G. Ceci, E. Corgna, R. Lottici, F. Papadia, M. Sofra, and M. Bacchi, DTIC Vs DTIC plus tamoxifen in metastatic malignant melanoma — A perspective randomized trial of the italian oncology group for clinical research, 2nd Int. Conf. on Melanoma, Venice 16–19 oct. 1989, Abst. pg. 325.Google Scholar
  33. 33).
    C.J. Rosenthal, A. Ohri and M. Rothman, Phase I study of DTIC by continuous infusion and concomitant radiation therapy, ASCO Proc. 6: 43 (1987).Google Scholar
  34. 34).
    D.B. Thomson, R.C. McLeod, and P. Hersey, Phase I/II study of tolerability and efficacy of recombinant interferon with dacarbazine in advanced malignant melanoma, ASCO Proc. 6: 208 (1987).Google Scholar
  35. 35).
    E. Bajetta, E. Negretti, B. Giannotti, L. Brogelli, I. Brunetti, M.R. Sertoli, M.G. Bernengo, M.C. Sofra, G. Maifredi, G. Zumiani, G. Cornella, R. Buzzoni, and N. Cascinelli, Phase II study of interferon alpha 2-a and dacarbazine (DTIC) in metastatic melanoma, ASCO Proc. 8: 286 (1989).Google Scholar
  36. 36).
    R. Kerr, P. Pippen, R. Mennel, and S. Jones, Treatment of metastatic malignant melanoma with a combination of interferon alpha 2-a (Roferon) and dacarbazine (DTIC), ASCO Proc. 8: 288 (1989).Google Scholar
  37. 37).
    N.E.J. Papadopoulos, J. Howard, J.L. Murray, C. Plager, S. Legna, J. Reuben, J.U. Gutterman, and R.S. Benjamin, Phase I–II DTIC and interleukin-2 (IL-2) trial for metastatic malignant melanoma, ASCO Proc. 8: 290 (1989).Google Scholar
  38. 38).
    D.A. Vorobiof and G. Falkson, DTIC versus DTIC and recobinant interferon α2b in the treatment of patients with advanced malignant melanoma, 5t h Europ. Conf. Clin. Oncol. ECCO5, London 3–7 sept. 1989, Abst. O-0714Google Scholar
  39. 39).
    G. Sava, T. Giraldi, L. Perissin, S. Zorzet, F. Mallardi, and V. Grill, Infiltration of the liver and brain by tumor cells in leukemic mice: prevention by dimethyltriazenes and cyclophosphamide, Tumori 70: 477 (1984).PubMedGoogle Scholar
  40. 40).
    T. Giraldi, G. Sava, E. Mitri, and R. Cherubino, Hemostasis and mechanism of action of selective antimetastatic drugs in mice bearing Lewis lung carcinoma, Eur. J. Cancer Clin. Oncol. 20: 961 (1984).PubMedCrossRefGoogle Scholar
  41. 41).
    G. Sava, T. Giraldi, L. Lassiani, and C. Nisi, Antimetastatic action and hematological toxicity of p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide used as prophylactic adjuvants to surgical tumor removal in mice bearing B16 melanoma, Cancer Res. 44: 64 (1984).PubMedGoogle Scholar
  42. 42).
    M.S. Mitchell, M.B. Mokyr, and J.M. Davis, Effect of chemotherapy and immunotherapy on tumor specific immunity in melanoma, J. Clin. Invest. 59: 1017 (1977).PubMedCrossRefGoogle Scholar
  43. 43).
    J. Berkelhammer, M.J. Mastrangelo, R.E. Bellet, and R.T. Prehn, Chemoimmunotherapy increases the lymphocyte reactivity of melanoma patients, J. Cancer Clin. Oncol. 15: 197 (1979).Google Scholar
  44. 44).
    G. Cartei, T. Giraldi and R. Carrella, Effects of dacarbazine (DTIC) on immunology in the human. I: high intermittent dose (HID), International Conference on Triazenes; Chemical, Biological and Clinical Aspects, Trieste 28–29 nov. 1989, Abst. P2, in pressGoogle Scholar
  45. 45).
    G. Cartei, T. Giraldi and R. Carrella, Effects of dacarbazine (DTIC) on immunology in the human. II: low and intermediate chronic dose schedule, International Conference on Triazenes; Chemical, Biological and Clinical Aspects, Trieste 28–29 nov. 1989, Abst. P3, in pressGoogle Scholar
  46. 46).
    U. Veronesi, C. Aubert, E. Bajetta, G. Beretta, G. Bonadonna, N. Cascinelli, J. De Marsillac, R.L. Ikonopisov, B. Kiss, T. Krementz, F. Lejeune, Z. Mechi, G.W. Milton, A. Morabito, P. Mulder, P. Pawlicki, J. Priario, P. Rumke, R. Sertoli, R. Tomin, N. Trapeznikov, and R. Wagner, (WHO collaborating centres for evaluation of methods of diagnosis and treatment of melanoma) controlled study with imidazole carboxamide (DTIC), DTIC + Bacillus Calmette Guerin (BCG) and DTIC + Corynebacterium parvum in advanced melanoma, Tumori 70: 41 (1984).Google Scholar
  47. 47).
    F.J. Lejeune, Malignant melanoma, in: “Randomized trials in cancer, a critical review by sites,” M.L. Slevin and M.J. Staquet, eds., Raven Press, New York (1986).Google Scholar
  48. 48).
    R.L. Comis, DTIC (NSC 45388) in malignant melanoma, a propsective. Cancer Treat. Rep. 60: 165 (1976).PubMedGoogle Scholar
  49. 49).
    G.M.B. Durie, L. Clouse, T. Braich, M. Grimm, and A.B. Robertone, Intereferon alpha2b and cyclophosphamide combination studies: in vitro and phase I–II clinical results, Seminars Oncology 13: 84 (1986).Google Scholar
  50. 50).
    G. Zupi, A. Corsi, A. Sacchi, L. Lassiani, and T. Giraldi, Effects of dimethyltriazenes on in vitro Lewis lung carcinoma lines with different metastatic capacity, Invasion Metastasis 4: 179 (1984).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1990

Authors and Affiliations

  • G. Cartei
    • 1
  1. 1.Divisione di OncologiaOspedale Civile di Udine Piazza Santa Maria della MisericordiaUdineItaly

Personalised recommendations